

Collaboration Opportunity: NTRK Lab Benchmarking | Netherlands

In recent years, pan-tumor NTRK gene fusions have emerged as targets for cancer therapy however, these gene fusions can be “promiscuous” and have multiple fusion partners thus making accurate detection difficult. Whilst immunohistochemistry (IHC) and Next Generation Sequencing (NGS) are the two methods commonly used for detection of these gene fusions, variation exists between laboratories with regards to how these methods are adopted i.e.

1. Some labs use IHC as a first stage screening tool before testing with NGS
2. A spectrum of NGS technologies (RNA versus DNA based) are used depending on existing in-house lab expertise

Why join the collaboration:

Work with your local peers who are performing NTRK testing and have chosen to participate in this collaboration and a Diaceutics team to design a benchmark report that will provide insight as to the status of National NTRK testing i.e.

- ✓ Which samples are tested for NTRK gene fusions?
- ✓ What algorithms are adopted by labs for NTRK gene fusion testing?
- ✓ What methods/commercial assays are used for NTRK gene fusion testing?

Please note: This collaboration will only begin once a minimum of 5 labs have registered interest and been enrolled.

Additional information

To be eligible to participate in this collaboration please ensure that:

- ✓ Lab profile information reflects:
 - ⊗ Available in-house IHC auto-stainer and NGS platform details
 - ⊗ External Quality Assurance (EQA) schemes or proficiency testing (PT) programs that are being subscribed to for NTRK gene fusion testing
- ✓ Lab assay details reflecting
 - ⊗ Current NTRK testing methods and turnaround times
 - ⊗ Scoring algorithms and reporting formats
 - ⊗ Q1 & Q2 2020 NTRK volumes for indications covered within your service

*Please note, where multiple assays are available in-house, these must be logged as individual assays per technology

Collaboration process



Register interest on DXRX

Click register interest on DXRX




Enrollment onto lab benchmark collaboration zone

Diaceutics will activate collaboration zone enrolment once eligibility check has been



Completion of primary survey

Gathering of initial insights to support design of lab benchmark



Review of draft benchmark report

Feedback pertaining to draft design together with gathering of additional suggestions to optimize insights



Finalization of benchmark report

Q1 2021. This may vary depending on when the collaboration is initiated

[Discover DXRX Collaborations](#)